Levin Capital Strategies L.P. Has $6.30 Million Stock Holdings in Aura Biosciences, Inc. $AURA

Levin Capital Strategies L.P. reduced its position in shares of Aura Biosciences, Inc. (NASDAQ:AURA) by 9.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 941,400 shares of the company’s stock after selling 94,186 shares during the period. Levin Capital Strategies L.P. owned about 1.47% of Aura Biosciences worth $6,298,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in AURA. Parallel Advisors LLC boosted its position in Aura Biosciences by 130.4% during the 1st quarter. Parallel Advisors LLC now owns 5,665 shares of the company’s stock worth $38,000 after buying an additional 3,206 shares during the period. Tower Research Capital LLC TRC increased its position in Aura Biosciences by 49.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock valued at $40,000 after acquiring an additional 2,104 shares during the period. ProShare Advisors LLC bought a new position in shares of Aura Biosciences during the fourth quarter valued at $59,000. Water Island Capital LLC bought a new position in shares of Aura Biosciences during the third quarter valued at $64,000. Finally, Invesco Ltd. bought a new position in shares of Aura Biosciences during the second quarter valued at $76,000. Institutional investors and hedge funds own 96.75% of the company’s stock.

Aura Biosciences Trading Down 0.3%

Shares of Aura Biosciences stock opened at $7.01 on Thursday. The business has a 50-day moving average price of $7.02 and a two-hundred day moving average price of $6.50. Aura Biosciences, Inc. has a 1-year low of $4.73 and a 1-year high of $9.53. The company has a market cap of $724.76 million, a P/E ratio of -4.03 and a beta of 0.40.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.10). Equities research analysts forecast that Aura Biosciences, Inc. will post -1.73 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on AURA. Wall Street Zen cut shares of Aura Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, July 12th. Leerink Partners set a $17.00 target price on Aura Biosciences in a report on Tuesday, May 12th. Weiss Ratings upgraded Aura Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 14th. Finally, HC Wainwright increased their price target on Aura Biosciences from $22.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Aura Biosciences currently has an average rating of “Hold” and an average price target of $20.50.

Insider Buying and Selling

In other Aura Biosciences news, major shareholder Matrix Capital Management Comp sold 6,922,870 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $5.64, for a total value of $39,044,986.80. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Anthony S. Gibney sold 12,824 shares of the stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $6.42, for a total value of $82,330.08. Following the transaction, the insider owned 265,354 shares in the company, valued at $1,703,572.68. The trade was a 4.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 1.90% of the company’s stock.

Aura Biosciences Profile

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.